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SHORT REPORT
Sideroflexin 3 is an α-synuclein-dependent mitochondrial protein
that regulates synaptic morphology
Inês S. Amorim1,2, Laura C. Graham2,3, Roderick N. Carter4, Nicholas M. Morton4, Fella Hammachi5, Tilo Kunath5,
Giuseppa Pennetta1,2, Sarah M. Carpanini3, Jean C. Manson3, Douglas J. Lamont6, Thomas M. Wishart2,3 and
Thomas H. Gillingwater1,2,*
ABSTRACT
α-Synuclein plays a central role in Parkinson’s disease, where it
contributes to the vulnerability of synapses to degeneration. However,
the downstream mechanisms through which α-synuclein controls
synaptic stability and degeneration are not fully understood. Here,
comparative proteomics on synapses isolated from α-synuclein−/−
mouse brain identified mitochondrial proteins as primary targets of
α-synuclein, revealing 37 mitochondrial proteins not previously linked
to α-synuclein or neurodegeneration pathways. Of these, sideroflexin
3 (SFXN3) was found to be a mitochondrial protein localized to the
inner mitochondrial membrane. Loss of SFXN3 did not disturb
mitochondrial electron transport chain function in mouse synapses,
suggesting that its function in mitochondria is likely to be independent
of canonical bioenergetic pathways. In contrast, experimental
manipulation of SFXN3 levels disrupted synaptic morphology at the
Drosophila neuromuscular junction. These results provide novel
insights into α-synuclein-dependent pathways, highlighting an
important influence on mitochondrial proteins at the synapse,
including SFXN3. We also identify SFXN3 as a new mitochondrial
protein capable of regulating synaptic morphology in vivo.
KEY WORDS: Alpha-synuclein, Sideroflexin 3, Neurodegeneration,
Synapse, Mitochondria
INTRODUCTION
α-Synuclein is an abundant neuronal protein with a central role
in the pathophysiology of Parkinson’s disease. Abnormal
accumulation of protein aggregates containing α-synuclein in
Lewy bodies is a pathological hallmark of Parkinson’s disease,
and mutations and multiplications of SNCA, the gene encoding
α-synuclein, have been linked with familial cases of the disease
(Stefanis, 2012). The physiological and neurotoxic functions of
α-synuclein have been associated with a variety of cellular
processes, including neurotransmission, protein degradation and
mitochondrial function (Lashuel et al., 2013; Stefanis, 2012).
For example, α-synuclein has previously been shown to affect
mitochondrial functions including complex I activity, oxidative
stress and protein import pathways (Di Maio et al., 2016; Liu et al.,
2009; Parihar et al., 2008).
At the level of the synapse,α-synuclein supports neurotransmission
by promoting SNARE complex assembly and regulating synaptic
vesicle recycling andmobility (Burré et al., 2014;Murphyet al., 2000;
Scott and Roy, 2012). However, whereas increased levels of α-
synuclein attenuate the neurodegenerative phenotype caused by
deletion of CSP-α (also known as DNAJC5) (Chandra et al., 2005),
both increased expression and deletion ofα-synuclein impair synaptic
functions (Burre et al., 2010; Cabin et al., 2002; Nemani et al., 2010).
Therefore, the molecular mechanisms through which α-synuclein
influences synaptic form and function remain unclear.
Here,we have undertaken a proteomics screen to identifymolecular
pathways and proteins acting downstream of α-synuclein in synapses,
identifying synaptic mitochondria and the mitochondrial protein
SFXN3 as an important target.
RESULTS AND DISCUSSION
Identification of novel α-synuclein targets at the synapse
To uncover molecular mechanisms downstream of α-synuclein
relevant for synaptic form and function, we quantified changes in the
synaptic proteome of mice lacking α-synuclein (Fig. 1A). iTRAQ
proteomics on synaptosomes from α-syn+/+ and α-syn−/− mice
identified 2615 individual proteins. Raw mass spectrometry data was
filtered to leave only those proteins identified by at least two unique
peptides and with expression levels consistently altered by ≥15%
across two independent technical replicates (Table S1). The remaining
200 proteins were submitted to bioinformatics pathway analysis
through ingenuity pathway analysis (IPA), DAVID and VarElect,
revealing a striking enrichment of proteins (74 out of 200) belonging to
mitochondrial pathways (Table 1; Table S1). This provides substantial
experimental support for the hypothesis thatα-synuclein has important
physical and/or functional interactionswithmitochondria (Haelterman
et al., 2014; Nakamura, 2013). Further bioinformatics analysis
identified 37 mitochondrial proteins not previously associated with
α-synuclein or neurodegeneration (Fig. S1).
To select individual proteins from the shortlist of 37 to be
prioritized for further analyses, we performed extensive literature
searches to identify those with potential links to Parkinson’s
disease and/or neurodegeneration. Using this approach,
sideroflexin 3 (SFXN3) was identified as a protein of particular
interest. Studies have reported that levels of SFXN3 transcripts or
protein were deregulated in the substantia nigra of Parkinson’s
disease patients and in rodents subjected to a 6-hydroxydopamineReceived 22 June 2016; Accepted 17 November 2016
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lesion (Charbonnier-Beaupel et al., 2015; Fuller et al., 2014;
Simunovic et al., 2009). SFXN1, a protein from the same family,
interacts with connexin 32 (also known as GJB1), mutations in
which cause Charcot–Marie–Tooth disease (Bergoffen et al.,
1993; Fowler et al., 2013), and reduced levels of SFXN1 protein
have been reported in Alzheimer’s disease (Minjarez et al., 2016).
In addition, SFXN2 is upregulated in a dopaminergic cell line in
response to rotenone treatment (Jin et al., 2007). SFXN3 belongs
to a family of proteins (sideroflexins 1–5) that are putative iron
transporters, with predicted transmembrane domains and
mitochondrial localization (Fleming et al., 2001; Li et al., 2010).
The functional role of these proteins, however, remains poorly
understood.
Levels of SFXN3 protein were increased in synapses from α-
syn−/− mice (Fig. 1B), suggesting that SFXN3 expression is
inversely correlated with α-synuclein. To confirm this, we
overexpressed wild-type α-synuclein in stably transfected SH-
SY5Y cells. Exposure of SH-SY5Y cells to doxycycline (DOX) for
24 h led to a significant increase in α-synuclein (5.78±0.81; n≥9;
mean±s.e.m.; P=1.7×10−6 in t-test), accompanied by a significant
decrease in levels of SFXN3 protein (Fig. 1C). Thus, SFXN3 levels
are bi-directionally regulated by α-synuclein.
It is not clear how α-synuclein regulates levels of SFXN3. One
possibility is that α-synuclein interferes with the import of SFXN3
into mitochondria, given that α-synuclein has been shown to
inhibit the import of nuclear-encoded mitochondrial proteins
through an interaction with TOMM20 (Di Maio et al., 2016). In
support of this, we found several mitochondrial import proteins,
such as TIMM10B, PAM16 and TOMM40, to be upregulated in
α-syn−/− mice compared to controls (Table S1).
Fig. 1. Loss of α-synuclein at the
synapse leads to widespread
disruption of mitochondrial proteins,
including SFXN3. (A) Schematic
overview of experimental design. iTRAQ,
isobaric tag for relative and absolute
quantitation. (B) SFXN3 protein levels
were significantly upregulated in
synaptosomes from α-syn−/− compared
to α-syn+/+ controls. ****P<0.0001
(unpaired t-test). Cox IV, loading control.
(C) SFXN3 protein levels were
significantly reduced in SH-SY5Y cells
overexpressing WT α-synuclein induced
by doxycycline (+DOX). ***P<0.001
(unpaired t-test). Actin, loading control.
(D) Representative western blot showing
SFXN3 expression across several tissues
from an adult wild-type mouse. Cox IV
was used as a mitochondrial marker. (E)
SFXN3 was exclusively localized to
mitochondrial (Mito), but not cytosolic
(Cyt), fractions isolated frommouse brain.
Cox IV was used as a mitochondrial
marker and GAPDH as a cytosolic
marker. (F) SFXN3 was exclusively
localized to the inner mitochondrial
membrane. Outer mitochondrial
membrane (OMM) and mitoplasts (Mit.)
were isolated from undifferentiated SH-
SY5Y cells. VDAC2 was used as a
marker for the OMM and ATP5A as a
marker for the mitoplast fraction. All data
are mean±s.e.m.
Table 1. Pathway and Gene Ontology analyses reveal an enrichment of
mitochondrial proteins with modified levels in synapses lacking
α-synuclein
P-value
IPA top canonical pathways
Mitochondrial dysfunction 9.36×10−8
TCA cycle II (eukaryotic) 2.01×10−6




Generation of precursor metabolites and energy 2.30×10−9
Transmission of nerve impulses 8.13×10−7
Oxidative reduction 2.23×10−6
Synaptic transmission 2.96×10−6
Regulation of neurotransmitter levels 3.92×10−6
Electron transport chain 2.46×10−5
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SFXN3 is a mitochondrial protein enriched in the inner
mitochondrial membrane
SFXN3 is predicted to be a mitochondrial protein (Pagliarini et al.,
2008), but experimental evidence confirming its tissue expression
and subcellular localization is lacking. We used western blotting to
analyse expression levels of SFXN3 protein in mice (Fig. 1D).
SFXN3 was highly enriched in brain, both in synaptic and non-
synaptic fractions, spinal cord and peripheral nerve. It was also
present in liver and kidney, but was not detectable in skeletal or
cardiac muscle.
Isolation of mitochondrial and cytosolic fractions from mouse
brain confirmed that SFXN3 was expressed exclusively in
mitochondria (Fig. 1E). Furthermore, differential extraction of
mitochondrial outer membrane andmitoplasts of mitochondria from
SH-SY5Y cells revealed that SFXN3 was localized to the mitoplast
fraction (Fig. 1F). Given the presence of transmembrane domains in
the SFXN3 protein (Li et al., 2010), we conclude that SFXN3 is
preferentially localized to the inner mitochondrial membrane.
Loss of SFXN3 does not influence mitochondrial
bioenergetics
The localization of SFXN3 to the inner mitochondrial membrane
prompted us to ask whether SFXN3 plays a role in canonical
bioenergetic pathways, including oxidative phosphorylation. We
isolated purified synaptosomes from wild-type (WT) and SFXN3-
knockout (KO) mice and performed mitochondrial respiration
Fig. 2. Loss of SFXN3 does not affect mitochondrial bioenergetics. (A) Identical oxygen consumption rates (OCR) in synaptosomes fromWTand SFXN3-KO
mice. Dashed vertical lines indicate the time of injection of Oligomycin (Oligo), FCCP (FCCP) and antimycin A (AA). n=3. (B) Bioenergetic parameters
derived from results in A (see Materials and Methods). n=3, P>0.05 (unpaired t-test). (C) Complex I activity measured by tracking absorbance of oxidized
NADH. n=3. (D) Rate of Complex I activity derived from results in C shows that the enzymatic activity of Complex I is not compromised in SFXN3-KO mice. n=3,
P>0.05 (unpaired t-test). (E) Complex IV activity measured by tracking absorbance of reduced cytochrome c. n=3. (F) Rate of Complex IV activity derived from
results in E shows that the oxidation of cytochrome c is not affected in SFXN3-KO mice. n=3, P>0.05 (unpaired t-test). (G,H) Western blotting showing unaltered
levels of key ETC proteins in synaptosomes from SFXN3-KO mice. n=3, P>0.05 (unpaired t-test). All data are mean±s.e.m.
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assays using a Seahorse XFe24 Analyzer. Oxygen consumption
rates (OCR) during basal respiration were similar between WT and
SFXN3-KO mice (Fig. 2A). Accordingly, the fraction of ATP-
linked respiration was comparable in WT and SFXN3-KO mice
(Fig. 2B). Uncoupling of mitochondria, by using FCCP, induced
equivalent spare and maximum respiratory OCR rates in WT and
SFXN3-KO synaptosomes, indicating that synaptic mitochondria
from SFXN3-KO mice are comparable to those from controls with
Fig. 3. Sfxn3 regulates synaptic morphology at the neuromuscular junction in Drosophila. (A,B) NMJs on muscles 6 and 7 (A) and 12 (B) of control and
transgenic larvae, with low (TgOE+) and high (TgOE++) overexpression of SFXN3. Note the reduction in boutons in TgOE++ NMJs (grey, anti-HRP; yellow,
pseudo-coloured synaptic boutons). Scale bars: 10 μm. (C–H) Reduction in the number of boutons and increase in mean bouton diameter on NMJs frommuscles
6 and 7 (C,D) and 12 (F,G) overexpressing SFXN3 (TgOE++). Results are mean±s.e.m. **P<0.01, ***P<0.001 (one-way ANOVA with Tukey post-test).
Distribution of bouton diameter from NMJs on muscles 6 and 7 (E) and 12 (H) showing a specific reduction of small size (<1.5 μm) boutons in TgOE++ larvae.
(I) Representative images of eyes from control and TgOE++ flies demonstrating no overt phenotype.
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respect to their ability to cope with short periods of high energetic
demand (Fig. 2A,B). Thus, SFXN3 is not absolutely required for
mitochondrial bioenergetics pathways, as mitochondrial respiration
was unaffected by the absence of SFXN3.
To confirm that subtle effects on mitochondrial respiration
prompted by reduced levels of SFXN3 were not being masked by
compensatory mechanisms in enzymatic activity or abundance of
other key electron transport chain (ETC) proteins, we performed
enzymatic assays on immunocaptured Complex I and Complex IV
(Fig. 2C,E). The rates of NADH and cytochrome c oxidation revealed
identical enzymatic activities of Complex I and Complex IV,
respectively, in WT and SFXN3-KO mice (Fig. 2D,F). Quantitative
western blotting for ATP5A (a component of ATP synthase), and the
Complex I and IV proteins NDUFB8 and Cox IV confirmed that no
compensatory changes were occurring in these ETC proteins in
SFXN3-KO mice (Fig. 2G,H).
SFXN3 influences synaptic morphology at the Drosophila
neuromuscular junction
Given that SFXN3 was identified as a α-synuclein target in synaptic
mitochondria, we wanted to establish whether SFXN3 contributes to
pathways regulating synaptic stability. We obtained and mapped a
UAS-driven P{EPgy2} Drosophila strain demonstrating insertion of
the promoter in the correct direction and in the 5′UTR of our gene of
interest, suggesting significant potential for overexpression of SFXN3
(Drosophila homologue of the sideroflexin gene; FlyBase annotation
CG6812). The Drosophila UAS-Gal4 system was used to generate
tissue-specific overexpression of SFXN3 in third-instar larval neurons
using the pan-neuronal driverelav-Gal4.High-dose overexpression of
SFXN3 (TgOE++) led to a significant reduction in the number of
synaptic boutons, accompanied by an overall increase inmean bouton
diameter, at the neuromuscular junctions (NMJs) frommuscles 6 and
7 and from muscle 12 (Fig. 3). The most striking phenotype was a
reduction in type II boutons innervating muscle 12. To confirm that
these changes were occurring as a direct result of changes in SFXN3
levels, we repeated our analyses with a low dose overexpression of
SFXN3 (TgOE+). These experiments confirmed no alterations in any
of the neuromuscular parameters analysed (Fig. 3). Furthermore,
analysis of eye morphology in TgOE++ flies showed no overt
phenotype (Fig. 3I). TheDrosophila eye is a robust and sensitive read-
out for identifying neurodegeneration (Sanhueza et al., 2015),
suggesting that overexpression of SFXN3 selectively influences
synaptic morphology without initiating neurodegenerative cascades.
Taken together, our results demonstrate an important role for α-
synuclein in regulating mitochondrial proteins at the synapse. We
identify SFXN3 as one mitochondrial protein whose levels are bi-
directionally regulated by α-synuclein and that is also capable of
directly influencing synapses in vivo. Further studies will now be
required to determine the extent to which SFXN3 acts as a
key intermediary of α-synuclein-dependent synaptic pathology
occurring in Parkinson’s disease. Considering that α-synuclein
itself is difficult to target from a therapeutic perspective (as a result of
being intrinsically disordered, with diverse and poorly understood
oligomeric states), targeting SFXN3 might ultimately represent an
alternative strategy for maintaining synapses in Parkinson’s disease.
MATERIALS AND METHODS
Reagents
All chemicals were purchased from Sigma Aldrich, except tissue culture
reagents, the BCA assay, RIPA buffer and Halt protease inhibitor cocktail,
which were from Thermo Scientific, and Percoll, which was from GE
Healthcare Biosciences. Buffer compositions are in Table S2.
Mice
C57Bl/6J (α-syn+/+) andC57Bl/6JOlaHsd (α-syn−/−)mice, carrying a natural
α-synuclein deletion (Specht and Schoepfer, 2001), were obtained from
Universityof Edinburgh breeding stocks. Sfxn3tm1b(KOMP)Wtsi mice (SFXN3-
KO mice; http://www.mousephenotype.org/data/genes/MGI:2137679) were
obtained from theWellcomeTrust Sanger InstituteMouseGenetics Project as
part of the nPad MRC Mouse Consortium, maintained on a C57Bl/6N
background. Mice were of mixed gender and 2–4 months old. All work was
covered by appropriate UK Home Office licenses.
Drosophila
Drosophila melanogaster were raised on standard cornmeal food at room
temperature. elav-Gal4 and GMR-Gal4 driver strains were used with stocks
obtained from the Bloomington Drosophila stock center (IDs: y1 w67c23;
P{EPgy2}CG6812EY02703; Canton-S). Crosses were maintained at 22°C for
24 h before removal of adults and embryos were incubated in a water bath to
increase levels and activity of Gal4 proteins. Incubation temperatures were
25°C or 30°C for low dose (TgOE+) or high dose (TgOE++) overexpression
experiments, respectively. For immunohistochemistry methods see
Sanhueza et al. (2015). Images were analysed using IMARIS software to
determine the number and transverse diameter of synaptic boutons. The
investigator was blinded to the group allocation throughout.
Isolation of synaptosomes and iTRAQ proteomics analysis
Isolation of crude synaptosomes from α-syn+/+ and α-syn−/− mice was
performed as described previously (McGorum et al., 2015; Wishart et al.,
2012). Samples were homogenized in iTRAQ buffer and supernatant
extracts from four mice per genotype were pooled. 100 μg protein was
labelled with tags (114 and 116 α-syn+/+; 115 and 117 α-syn−/−) before
injection into an Ultimate RSLC nano UHPLC system coupled to a LTQ
Orbitrap Velos Pro (Thermo Scientific). Results were filtered to include
proteins identified by at least two unique peptides with a≥15% difference in
levels across both α-syn+/+ vs α-syn−/− comparisons.
Data were examined using bioinformatics tools: ingenuity pathway
analysis (IPA; Ingenuity Systems, USA); Database for Annotation,
Visualization and Integrated Discovery (DAVID; NIH, USA); and
VarElect (LifeMap Sciences, USA). IPA was used to determine affected
molecular pathways (Top Canonical Pathways). DAVID Functional
Annotation was used to identify enrichment for gene ontology (GO)
terms. VarElect was used to identify the fraction of data that included
proteins associated with the terms ‘mitochondria’ and the group of terms
‘Parkinson’s’, ‘Parkinson’, ‘PD’, ‘synuclein’ and ‘SNCA’.
Tissue culture
SH-SY5Y cells were electroporated with a Tet-One™ plasmid (Clontech)
encoding full-length human α-synuclein and a DOX-responsive clonal line
was selected and maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS), 1% penicillin-
streptomycin, 1 mM sodium pyruvate and 2 µg/ml puromycin. For induction
of α-synuclein expression, 24 h after plating cells were differentiated for
5 days in the presence of 10 µM retinoic acid and incubated in DMEM
supplemented with 10 µg/ml of doxycycline for 24 h.
Isolation and fractionation of mitochondria
Mitochondria were isolated from mouse brain using the Mitochondria
Isolation Kit for Tissue (Abcam). Fractionation of mitochondria from
undifferentiated SH-SY5Y cells was performed as described previously
(Nishimura et al., 2014).
Western blotting
Western blotting was performed as described previously (Eaton et al., 2013),
using antibodies in Table S3.
Mitochondrial respiration assays
Mitochondrial respiration assays were performed on purified synaptosomes,
isolated from mouse forebrain using discontinuous Percoll gradients
prepared in isolation medium, as previously described (Choi et al., 2009).
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Synaptosomes (10 μg protein/well, ≥5 technical replicas per sample)
were loaded intowells of XFe24 V7 (Seahorse Biosciences) uncoated plates.
The plate was centrifuged at 2000 g for 20 min at 4°C, and 500 μl of
incubation medium was added to each well prior to entry into the XFe24
Seahorse Analyzer (Seahorse Biosciences). Oxygen consumption rates
(OCR) were measured in groups of two cycles of 1 min wait, 1 min mix,
3 min measurements, with an injection between each 2 cycles. Each well
was sequentially exposed to 4 μg/ml oligomycin to stop ATPsynthase
activity, 4 μM FCCP to dissipate mitochondrial membrane potential and
potentiate maximum oxidative phosphorylation activity, and 4 μg/ml
antimycin A to inhibit complex IV and completely stop mitochondria
oxidative phosphorylation. OCR values for each injection step were
calculated as the mean of the measurements of two cycles per injection
step and used to determine the following parameters: basal respiration (basal
mitochondrial respiration before addition of any compound); ATP-linked
respiration (basal minus oligomycin-induced rate, respiration rates
associated with the production of ATP by the ATP synthase); maximum
capacity (FCCP-induced minus antimycin-A-induced rate, maximum
respiratory capacity achieved by the activity of complex I–IV); and
spare capacity (FCCP-induced minus basal rate, mitochondria capacity
above basal levels that can be recruited in situations of high energetic
demand).
Enzymatic assays
Enzymatic assays were performed using the Complex I and IV Enzyme
Activity Microplate Assay kits (Abcam) according to the manufacturer’s
instructions.
Statistical analysis
Quantitative datawas collected usingMicrosoft Excel. Statistics for pathway
analysis and gene ontology enrichments were calculated by their respective
software, using the right-tailed Fisher’s exact test. All other statistics were
performed using GraphPad Prism® (detailed in the results section or figure
legends). Statistical significance was considered to be P<0.05.
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